
### [NCIT:C27639](http://purl.obolibrary.org/obo/NCIT_C27639)
**Label:** Transplant-Related Hematologic Malignancy

**Subclasses:** [NCIT:C27695](http://purl.obolibrary.org/obo/NCIT_C27695) (EBV-Related Clonal Post-Transplant Lymphoproliferative Disorder), [NCIT:C7249](http://purl.obolibrary.org/obo/NCIT_C7249) (Immunoblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7238](http://purl.obolibrary.org/obo/NCIT_C7238) (Monomorphic T/NK-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7248](http://purl.obolibrary.org/obo/NCIT_C7248) (Centroblastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7237](http://purl.obolibrary.org/obo/NCIT_C7237) (Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7239](http://purl.obolibrary.org/obo/NCIT_C7239) (Hodgkin-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C7245](http://purl.obolibrary.org/obo/NCIT_C7245) (Burkitt-Like Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7233](http://purl.obolibrary.org/obo/NCIT_C7233) (Monomorphic Post-Transplant Lymphoproliferative Disorder), [NCIT:C7244](http://purl.obolibrary.org/obo/NCIT_C7244) (Burkitt Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7247](http://purl.obolibrary.org/obo/NCIT_C7247) (Anaplastic Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7246](http://purl.obolibrary.org/obo/NCIT_C7246) (Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder), [NCIT:C7241](http://purl.obolibrary.org/obo/NCIT_C7241) (Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder), [NCIT:C7240](http://purl.obolibrary.org/obo/NCIT_C7240) (Plasma Cell Post-Transplant Lymphoproliferative Disorder), [NCIT:C7243](http://purl.obolibrary.org/obo/NCIT_C7243) (Classical Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder), [NCIT:C7242](http://purl.obolibrary.org/obo/NCIT_C7242) (Plasma Cell Myeloma Post-Transplant Lymphoproliferative Disorder), 

**Class expressions from DL-Learner:**

- [NCIT:C81193](http://purl.obolibrary.org/obo/NCIT_C81193) (Immunosuppression-Related Post-Transplant Toxicity) 54.55%
- Thing 52.66%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40110](http://purl.obolibrary.org/obo/NCIT_C40110) (Borderline Fallopian Tube Endometrioid Tumor))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40108](http://purl.obolibrary.org/obo/NCIT_C40108) (Borderline Fallopian Tube Mucinous Tumor))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40107](http://purl.obolibrary.org/obo/NCIT_C40107) (Borderline Fallopian Tube Serous Tumor/Atypical Proliferative Serous Tumor))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40104](http://purl.obolibrary.org/obo/NCIT_C40104) (Fallopian Tube Transitional Cell Carcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40103](http://purl.obolibrary.org/obo/NCIT_C40103) (Fallopian Tube Mucinous Adenocarcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40093](http://purl.obolibrary.org/obo/NCIT_C40093) (Ovarian Squamous Cell Carcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40090](http://purl.obolibrary.org/obo/NCIT_C40090) (Ovarian Seromucinous Carcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40086](http://purl.obolibrary.org/obo/NCIT_C40086) (Ovarian Clear Cell Cystadenofibroma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40083](http://purl.obolibrary.org/obo/NCIT_C40083) (Borderline Ovarian Clear Cell Cystadenofibroma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40082](http://purl.obolibrary.org/obo/NCIT_C40082) (Borderline Ovarian Clear Cell Adenofibroma with Intraepithelial Carcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C4008](http://purl.obolibrary.org/obo/NCIT_C4008) (Recurrent Gallbladder Carcinoma))) 49.92%
- [NCIT:C42607](http://purl.obolibrary.org/obo/NCIT_C42607) (Therapy-Related Toxicity) and (not ([NCIT:C40079](http://purl.obolibrary.org/obo/NCIT_C40079) (Ovarian Clear Cell Adenocarcinofibroma))) 49.92%


